International SMA Patient Registry

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2015 by Indiana University
Sponsor:
Collaborator:
Families of Spinal Muscular Atrophy
Information provided by (Responsible Party):
Indiana University ( Indiana University School of Medicine )
ClinicalTrials.gov Identifier:
NCT00466349
First received: April 24, 2007
Last updated: March 23, 2015
Last verified: March 2015
  Purpose

This is a registry of individuals affected by Spinal Muscular Atrophy (SMA) and/or family members of individuals affected by SMA. The purpose of the registry is to allow researchers studying the biological basis of SMA and potential therapies in SMA access to individuals interested in participating in research and/or experimental therapies. The International SMA Patient Registry is supported by Families of SMA.


Condition
Muscular Atrophy, Spinal

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Family-Based
Target Follow-Up Duration: 50 Years
Official Title: International Spinal Muscular Atrophy Patient Registry

Resource links provided by NLM:


Further study details as provided by Indiana University:

Primary Outcome Measures:
  • Study is a patient registry [ Time Frame: unlimited ] [ Designated as safety issue: No ]

Estimated Enrollment: 5000
Study Start Date: May 1986
Detailed Description:

This project is supported by Families of SMA.

The Registry functions as a liaison between patients and families interested in participating in research and researchers interested in studying SMA. The Registry contains information from 2,500 families and over 3,000 individuals with SMA from all over the world and continues to grow.

The Registry has helped recruit participants for clinical trials and has provided data for important SMA research studies. The Registry helps centralize information on this rare genetic disease, provides families a way to learn about research studies and provides researchers a way to find research participants.

Individuals and families affected by SMA are invited to join the Registry. Participants are asked to complete questionnaires about the symptoms, treatment, medications, and other experiences with SMA. Visit the Participant Portal for more information on how to sign up for the Registry! Participant information is stored in a secure database. Researchers who are interested in studying SMA can request two types of data from the Registry, de-identified information and identifiable information. De-identified information does not contain any names or personal identifiers, and can be given to researchers without having to contact Registry families. Identifiable information includes information that can identify you and will never be released without getting your written permission to do so. Identifiable information includes data such as names and dates of birth. Some researchers may also request contact with families to obtain specific information or to request participation in a research study. In these instances, the Registry will contact each potential participant to ask if they are willing to share their identifiable information for a research project.

The Registry recognizes the importance of global collaboration. Working together with researchers from all over the world is very important in the investigation of SMA. In 2008 the Registry joined the group, Translational Research in Europe for the Assessment and Treatment of Neuromuscular Diseases (TREAT-NMD) in a global collaboration to further the research goals of the neuromuscular disease community. TREAT-NMD has developed a global database that compiles deidentified data transferred from participating registries around the world. The main objective of the TREAT-NMD database is to assess the feasibility of clinical trials, to facilitate the planning of clinical trials and to support the enrollment of patients in clinical trials. This international database will also be used to answer questions regarding the prevalence of particular neuromuscular disorders and assessing the support of other activities such as assessing standards of care and diagnosis.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Individuals or family members of individuals who have been diagnosed with SMA.

Criteria

Inclusion Criteria:

  • Individuals or family members of individuals who have been diagnosed with SMA.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00466349

Contacts
Contact: Claire Wegel (317) 278-6158 smareg@iupui.edu
Contact: Connie Garland (317) 274-5745 smareg@iupui.edu

Locations
United States, Indiana
Indiana University School of Medicine Recruiting
Indianapolis, Indiana, United States, 46202
Contact: Connie Garland    866-482-0248    smareg@iupui.edu   
Sponsors and Collaborators
Indiana University School of Medicine
Families of Spinal Muscular Atrophy
Investigators
Principal Investigator: Tatiana Foroud, PhD Indiana University School of Medicine
  More Information

Additional Information:
No publications provided

Responsible Party: Indiana University ( Indiana University School of Medicine )
ClinicalTrials.gov Identifier: NCT00466349     History of Changes
Other Study ID Numbers: 0202-03
Study First Received: April 24, 2007
Last Updated: March 23, 2015
Health Authority: United States: Institutional Review Board

Keywords provided by Indiana University:
SMA Type I
SMA Type II
SMA Type III
SMN
Werdnig-Hoffman Disease
Spinal Muscular Atrophy
Registry
SMA Type IV

Additional relevant MeSH terms:
Muscular Atrophy, Spinal
Atrophy
Muscular Atrophy
Central Nervous System Diseases
Motor Neuron Disease
Nervous System Diseases
Neurodegenerative Diseases
Neurologic Manifestations
Neuromuscular Diseases
Neuromuscular Manifestations
Pathological Conditions, Anatomical
Signs and Symptoms
Spinal Cord Diseases

ClinicalTrials.gov processed this record on May 21, 2015